Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07150065

Enrollment

360

Registered

2025-09-02

Start date

2025-02-07

Completion date

2025-08-07

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fever, Typhoid

Keywords

ciprofloxacin, children, enteric fever, levofloxacin

Brief summary

Sample size of 360 children with typhoid fever were enrolled and randomly divided in two groups. All the children were enrolled in the trial from Pediatrics emergency. Informed consent was obtained from parents. Demographics (name, age of child, sex of the child, duration of fever, weight, season, socioeconomic status and residence) were noted. Then children were admitted and randomly divided in two groups by using lottery method. In group A, children were given oral 200 mg levofloxacin tablet. In group B, children were given oral 900-1,000 mg ciprofloxacin tablet. All children were followed-up pediatric wards for 7 days. If fever was resolved within 5 days (body temperature falls \<99oF and remain stable for at least 5 days), then efficacy was labeled. Total time required to resolve fever i.e. body temperature \<99oF in all children was also noted. All this information was recorded

Interventions

DRUGLevofloxacin

Oral 200 mg levofloxacin tablet

DRUGciprofloxacin

Oral 900-1,000 mg ciprofloxacin tablet

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

1 Years to 12 Years

Healthy volunteers

Inclusion criteria

* Children of age 1-12 years * Typhoid fever * Confirmed on blood culture

Exclusion criteria

* Recurrent typhoid within 3 months * Intestinal perforation * Evidence of progressive or complicated disease * Inability to swallow oral medication * Hypersensitivity to trial drugs * Already taken fluoroquinolone, third generation cephalosporin or macrolide in last week

Design outcomes

Primary

Measure	Time frame	Description
Total time required to resolve fever	5 days	Clinical efficacy involved resolution of fever within 5 days (body temperature falls \<99oF and remain stable for at least 5 days). Total time required to resolve fever i.e. body temperature \<99oF in all children was also noted.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026